Table 3.

PDE5 inhibitors oral single dose in clinical trials.

Drugs	Doses	Field	Phase	Patients	References and ID clinical number
Sildenafil	100 mg	cognition	Completed Phase VI	Healthy males	Grass et al. 2001 [97]
Sildenafil	100 mg	cognition	Completed Phase VI	Healthy males	Schultheiss et al. 2001 [98]
Sildenafil	50 and 100 mg	schizophrenia	Completed Phase VI	Schizophrenic patients	Goff et al. 2009 [99]
Sildenafil	50 mg	Parkinson’s disease	Phase II (insufficient participants)	Parkinson’s disease patients	Identifier: NCT02162979
Sildenafil	50 mg	hemodynamic function	N/A	AD patients	Sheg et al. 2017 [101]
Sildenafil		ischemic stroke	Phase I (terminated due to non-recruitment of patients within the scheduled time period)	Ischemic stroke patients	Identifier: NCT00452582
Tadalafil	20 mg	cognition	Phase II	Elderly with small vessel disease	Identifier: NCT02450253
Vardenafil	10, 20 mg	sensory gating	Completed phase II	Healthy young adults	Reneerkens et al 2013 [105]
Vardenafil	10, 20 mg	cognition	Completed phase II	Healthy young adults	Reneerkens et al 2013 [106]
Udenafil	100 mg	cognition	N/A	Patients with ED	Shim et al 2011 [102]
Udenafil	50 mg	cognition	N/A	Patients with ED	Shim et al. 2014 [103]